My name is Andrea Penny Greenblatt, and I’ve had psoriatic arthritis for over 35 years. I’m also an Arthritis Foundation Advocate.

About four years ago, I joined the Medicare program and faced unexpectedly high out-of-pocket costs on Medicare Part D. Last March, when I participated in the Arthritis Foundation’s Advocacy Summit, I told as many people as I could about my challenge. At that time, there wasn’t much anyone could do since no solutions were being discussed. But I’ve been reading about what Congress is now trying to do to cap out-of-pocket costs, and I wanted to share my story so more patients like me don’t have to suffer.

自从加入医疗保险以来，我的总体医疗费用比我参加私人保险时要少。保费更低了，我去看医生和医生也没遇到什么麻烦。不幸的是，我最初进入这个项目的过渡是困难的，因为我的生物在医疗保险D部分的费用很高。我最初决定注册D部分，因为我的生物是一种注射药物，对我来说已经很有效，我不想破坏我的任何照顾。

我很快意识到，支付D部分药物的费用在经济上是一个挑战。最重要的是，我根本负担不起治疗我关节炎的药物的共同保险。共同保险几乎是40%!加剧这一问题的是，参加医疗保险的个人不允许从任何形式的共同支付援助中受益，这是我能够从我的前雇主那里获得的。

After discussing the prohibitive costs of the Part D drug with my doctor, we agreed I should consider transitioning to a physician-administered drug under Part B. I was nervous about abandoning the Part D drug, which had worked so well for me. It turns out my concerns were well-founded: After initial treatment with the Part B drug, I had unpleasant side effects. Since that infusion didn’t work, my doctor decided to try a second infused drug. The second drug seems to be helping, but it’s the only other alternative medication available, and I’m worried it could fail, too.

令人失望的是，D部分没有任何真正的自付限额来限制个人为药物支付的费用。我记得我的雇主医疗保险是相反的:在加入医疗保险之前，我每年要承担的费用有一个上限。医疗保险B部分一直是我的生命线，帮助我避免了经济困难。我很幸运有一个补充计划来限制我的开支，并帮助保持全年的开支更可预测。

The addition of an out-of-pocket cap in Medicare Part D is overdue. This change would make Medicare even more successful for me and millions of other Americans. If I had remained on the Part D medication four years ago, my monthly costs would have averaged $600-$700 per month. That’s simply too high for someone on a fixed income, especially when my costs would not be capped each year. My income today only allows for copayments of $200 at the most for my arthritis medication. In addition to an annual out-of-pocket cap, policymakers should consider ways that patients like me can spread costs throughout the entire year. That would help with affordability challenges and might allow me to go back to my Part D drug, which had worked so well to keep my disease at bay when I first joined Medicare.

There are days when I wish I could have afforded the Part D drug that was making a difference in my health. It turns out I’m not the only one: The Arthritis Foundation recently completed a survey showing thatother arthritis patients have experienced the same thing– forced to transition from Part D to Part B due to affordability issues. If you’ve had a similar experience on Medicare, sharing your story is so important. Your story helps raise awareness about access and affordability issues across the country. Here are some actions you can take:

• Share your story through the Arthritis Foundation!Your experience keeps us informed and helps us advocate together. TheLive Yes! Arthritis Networkbrings us all together.
• If you are unable to afford your prescription drugs, patient assistance programs may help. Visit the Arthritis Foundation’sAccess to Care toolkitfor help navigating all aspects of health coverage.
• Think about your options during open enrollment this year – the Arthritis Foundation has a greatblog from one of their Helpline social workers谈论重要的建议和技巧，以确保你选择正确的计划。

Tricia’s story is like many others trying to make arthritis coverage more affordable

My name is Tricia Mershon, and I live with my family in Corona, California. At the age of 3, my daughter, Rachel, was found to have a dysfunctional immune system. Her tiny body failed to mount a response to infection, and various disease specialists were able to document the phenomenon but unable to pinpoint a cause.

Just before ninth grade, Rachel’s fingers curved into a funny “s” shape and looked different than those of anyone else. When she began having pain in her feet, knees and hips, which sometimes made walking difficult, Rachel was promptly referred to rheumatology, and we found the real culprit. At 14, Rachel was diagnosed with juvenile idiopathic (rheumatoid) arthritis. She began aggressive treatment to halt the progression of this insidious disease.Continue readingHow to Change Unreasonable Insurance Rules→

Let’s face it: out-of-pocket costs for patients with chronic diseases like arthritis are consuming an ever-growing share of household spending. Lowering drug prices has been a central priority of Congress and the Administration this year, and while a lot of attention is paid to drug companies and insurers, the impact on the patient often gets lost. There may be a lot of chatter about list prices, rebates, and other technical terms, but at the end of the day the health care price that matters most to patients is the one coming out of their own pocket.Continue readingOut-of-Pocket Costs: An Out-of-this-World Problem→